Europe Anti-obesity Drugs Market

Europe Anti-obesity Drugs Market Size (2024 to 2029)

The European anti-obesity drugs market is anticipated to be worth USD 3.91 billion by 2029 from USD 1.45 billion in 2024, growing at a CAGR of 21.93% from 2024 to 2029.

The increasing prevalence of obesity is prompting the growth of the European anti-obesity drugs market. Obesity and overweight are the most common conditions occurring widely among people. Obesity leads to various chronic disease conditions which severely affect the patient's daily routine. Obesity leads to chronic conditions such as insulin resistance, hypertension, sleep cycle disturbances, arthritis, and certain cancer types. According to the Centers for Disease Control and Prevention (CDC), more than 650,000 obesity-associated cancers occur, of which more than 200,000 are men and 450,000 are women. Breast cancer was most associated with obesity cancer in women and colorectal cancer in men. These factors are driving the market demand for anti-obesity drugs.

According to WHO, 1 billion people are obese worldwide, of which 650 million are adults, 340 million are teenagers, and 39 million are children. However, WHO predicted by 2025, approximately 167 million people would be unhealthy due to overweight and obese conditions. The rise in obesity was due to modern lifestyles and unhealthy diets. Many developed countries are campaigning and bringing awareness among people regarding obesity and further health conditions that arise due to obesity to decrease obesity cases.

The growing investments to conduct Research and Development by the market participants is boosting the growth rate of the European market. The demand for weight-loss medicine has increased due to the awareness of obesity among people. Many organizations invest in research programs to develop effective anti-obesity drugs with minimal adverse effects. Medicinal professionals are prescribing anti-obesity drugs to balance chronic disease conditions. Various developments are under more effective clinical trials. Innovent Biologics Inc.'s phase 2 clinical study of mazdutide with a dose of 9 mg showed positive results in Chinese obese adults. Many European areas are accessible to obese patients. The need for new drugs in the market was more, which was influencing many key players to invest in R&D, which was propelling the market growth.

The increasing awareness regarding the treatment of obesity was projected to create opportunities for market growth. Obesity was leading to chronic diseases such as type 2 diabetes, cardiovascular diseases, and certain cancers. Appropriate plans can avoid raising awareness in people regarding chronic disease conditions. The Global Obesity Forum, the global obesity community, and the WHO worked together on the complexity of the disease and developed approaches to address this problem. The initiatives made by the organizations were increasing awareness regarding disease conditions.

Regulatory Drug approval policies are hampering the regional market growth. The strict regulatory policies for the approval of the new anti-obesity drugs are hindering market growth, which restricts the establishment of many companies. According to the European Medicines Agency (EMA), only three drug therapies are approved, unlike the U.S. FDA, which approved five. To approve the drug's significant effect on weight loss, many regulatory bodies consider 5% total weight loss. These rigid regulations limit R&D investments and impact new product launches. Another restraining factor hampering the market growth was the side effects caused by the drugs, such as increased blood pressure and heart rate. Many researchers are working on minimizing the side effects to increase people's health conditions.

The increasing number of alternatives with minimal side effects, such as naturopathy and homeopathy, are challenging for market growth. The stringent regulations are limiting the new market launches.

COVID-19 Impact on the Europe Anti-obesity Market

The Pandemic has shown a mixed impact on the European anti-obesity market. During COVID-19, most hospital visits were reduced, and healthcare services were shut down due to strict lockdown regulations where only emergency COVID cases were accepted by the hospitals. However, the increased use of telemedicine as a replacement for in-person hospital visits and online consultancies for medical professionals with a chance of online pharmacies had decreased the impact of the Pandemic on the market growth. Many pharmaceutical companies focused on maintaining the supply and demand of medicines during COVID-19 by pausing new launches and trials.

This research report on the European anti-obesity drugs market has been segmented and sub-segmented into the following categories.

Europe Anti-obesity Drugs Market - By Drug Type:

• Prescription Drugs
• OTC Drugs

Based on drug type, the prescription drugs segment accounted for the largest share of the European anti-obesity drugs market in 2023.

Europe Anti-obesity Drugs Market - By Distribution Channel:

• Hospitals Pharmacies
• Retail Pharmacies
• E-commerce

During the forecast period, the e-commerce segment is anticipated to hold a significant share of the European market.                

Europe Anti-obesity Drugs Market - By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Europe held the global market revenue in second position for the anti-obesity drugs market due to the presence of key players and increasing investments in the research and development sector. According to the WHO European Region report in 2022, overweight and obese affect nearly 60% of adults, and 7.9% are children under age five.

Germany dominated the European anti-obesity market as the primary key player; Novo Nordisk launched Wegovy, which gained a massive response in the market. The leading organizations are showing interest in investing in research and development to launch new drugs with high effectiveness. According to the United Nations, the cost related to obesity and overweight in all age groups is estimated to be worth USD 800 billion for the WHO European region by 2035. Germany was expected to dominate the market over the forecast period due to its new developments in the research sector.

France was deemed to have a prominent market share in the European regional market due to the increased number of obese patients. U.K., as a developed country, the increase in advancements in the technology of healthcare, which allows them to produce new drugs, was boosting the regional market value.

The government collaborating with the manufacturers, conducting campaigns, and educating the people regarding the disease severity and preventive measures drove the market demand in Italy and Spain countries. Increasing awareness regarding the disease and its causes and preventive measures are essential among people to reduce the risk of death

KEY MARKET PLAYERS:

Merck & Co. Inc., Eisai Co. Ltd., Orexigen Therapeutics Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche, Shionogi Inc., Norgine B.V., Pfizer Inc., Zafgen, Boehringer Ingelheim GmbH, Rena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Novo Nordisk A/S and Rhythm Pharmaceuticals are a few of the notable companies in the European anti-obesity drugs market.